SmallCapPodcast.com
AGORACOM Small Cap TV AGORACOM Small-Cap Gold and Resources TV Chinese Small Cap Stock TV
LISTEN NOW LISTEN NOW LISTEN NOW
Jun 17, 2020 | by admin | Permalink

Agoracom interviews CEOs of small cap companies.

In this episode of the Small Cap CEO Interviews podcast, AGORACOM speaks with MedX (TSX-V:MDX) VP of Corporate Development, Mike Druhan.

MedX (MDX:TSXV) is the “overnight 5-year success story” that most retail investors have never heard about … but that is all about to change in 2020, a year that is set to dwarf the $860,000 in revenue MDX generated in 2019.

What do they do? In layman’s terms, they’ve combined their skin cancer scanning device with proprietary software to create a telemedicine platform focused on skin cancer. In essence, you scan a troubling spot on your body and within 72 hours you can have both a prognosis and treatment completed – god forbid.

Sounds like a cool idea but does it work? Glad you asked. The platform was proven through a proof-of-concept trial in Norway where 109 pharmacies captured 80,000 scans and found 860 cases of melanoma.

2020 is shaping up to be both the Company’s best year ever and the beginning of something potentially great. Why?

1. MDX signed an exclusive distribution deal that led to the Company receiving its biggest order in history – 500 units. With much more expected to come due to minimum annual sales requirements.
2. MDX just did the same thing in Mexico on Monday.

Mike Druhan, Vice President of Corporate Development, believes more countries are set to follow. We’d love to tell you more but trust us when we tell you that we’ve saved the best for the interview.

Telemedicine is going to be a monster, disruptive industry this decade and MDX has the early upper hand in the world of skin cancer.

Watch this interview or listen by Podcast on Apple, Google, Spotify or your favourite podcaster.

Download This Episode

View Company Website

Visit Investor Relations Hub